ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

ACADIA Pharma reports robust Q3 earnings and outlines growth strategies

ACADIA Pharma's Q3 earnings reflect strong sales performance, a robust financial position, and a focus on advancing its pipeline assets for future growth.
The company's new CEO brings industry expertise and a vision for expansion, while challenges in market expansion and competition require strategic planning.
Opportunities for ACADIA Pharma lie in international expansion, pipeline development, and continued efforts to drive growth through effective commercial strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia released its Q322 earnings this week. Revenues of $131m and a net loss of $27.2m are about par for the course. Acadia's only approved drug Nuplazid is approved to treat Parkinson's Disease Psychosis. Several attempts to expand the label have not succeeded.

Acadia Pharmaceuticals: I Remain Cautiously Bullish After Q3 Updates

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.

Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO & Director Brendan Teehan - EVP, COO & Head, Commercial Kathie Bishop - SVP and Head, Rare Disease & External Innovation Srdjan Stankovic - President Mark Schneyer - EVP & CFO Conference Call Participants Jeff Hung - Morgan Stanley Neena Bitritto-Garg - Citi Ritu Baral - Cowen and Company Salveen Richter - Goldman Sachs Jay Olson - Oppenheimer Alex Nackenoff - Raymond James & Associates Marc Goodman - SVB Securities Gregory Renza - RBC Capital Markets Yatin Suneja - Guggenheim Securities Charles Duncan - Cantor Fitzgerald Sumant Kulkarni - Canaccord Genuity Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today.

ACADIA Pharmaceuticals, Inc. (ACAD) Q3 2022 Earnings Call Transcript

Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.

Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its President, Srdjan (Serge) Stankovic, M.D.

Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets.

Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D.

Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors

Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.

Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.

Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why

ATLANTA--(BUSINESS WIRE)---- $ACAD #AL001_mitigates_lithium_toxicities--Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 Targeting Alzheimer's; Pursuing Add'l Indications

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's Subjects

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is up 3.3% to trade at $17.60 at last check, as the broader market looks to extend its early October rally.

Why Acadia Pharmaceuticals Stock's Rally Could Have Legs

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals today announced the launch of Rett Revealed, a new awareness campaign that will highlight the lives of Rett patients through a photo mosaic designed by Emily Shifflet, a 27-year-old eye-gaze artist living with Rett syndrome. In honor of Rett syndrome awareness month, this October members of the community are encouraged to submit their photos capturing meaningful moments in their lives to RettRevealed.com to be compiled into the unique mosaic ar

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

ATLANTA--(BUSINESS WIRE)---- $ACAD #AL002--Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.

Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The FDA has granted a priority review and assigned a PDUFA (Prescription Drug User Fee Act) action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting. “We're pleased th

Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?

The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade

Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?

Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.

Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Kathie Bishop - SVP and Head, Rare Disease & External Innovation Srdjan Stankovic - President Stephen Davis - CEO & Director Mark Johnson - VP, IR Brendan Teehan - EVP, COO & Head of Commercial Mark Schneyer - EVP & CFO Conference Call Participants Jay Olson - Oppenheimer Marc Goodman - SVB Securities Tazeen Ahmad - Bank of America Merrill Lynch Ritu Baral - Cowen and Company Neena Garg - Citigroup Gregory Renza - RBC Capital Markets Sumant Kulkarni - Canaccord Genuity Charles Duncan - Cantor Fitzgerald & Co. Eddie Hickman - Guggenheim Securities Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. [Operator Instructions].

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2022 Results - Earnings Call Transcript

Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022. “In the second quarter of 2022, NUPLAZID net sales increased 17% year-over-year,” said Steve Davis, Chief Executive Officer. “Last month, we submitted an NDA for our second potential commercial product, trofinetide which would be the first FDA-approved treatment for Rett syndrome. Together with a strong balance sheet, our late and early-stage

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The CRL indicated that the FDA has completed review of the application, determining that it could not approve the

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease Psychosis

News for ACADIA Pharma Stock (ACAD)